Neil St. John Forbes

Associate Professor


N525 Life Sciences Laboratory (LSL)
Mailing Address:
Chemical Engineering Department
University of Massachusetts Amherst
686 N. Pleasant Street
Amherst, MA 01003-9303
413-577-0132 (office)
413-545-1647 (FAX)
forbes@ecs.umass.edu

 

FORBES RESEARCH GROUP

Education

B.S., Chemical Engineering, Case Western Reserve University, 1994
Ph.D., Chemical Engineering, University of California, Berkeley, 2000
Postdoctoral research, Radiation Oncology, Harvard Medical School

Current Focus of Research

Application of chemical engineering principles to the study of tumor formation and treatment is fertile new ground for research and is necessary for the advancement of cancer therapy. Over the last century, researchers have discovered many of the genetic causes of cancer and yet nearly 46,000 people will die this year from cancer in the United States alone. Standard cancer therapies often fail because of spatial heterogeneity of nutrients, wastes, and therapeutics. Transport barriers prevent therapeutic agents from reaching effective concentrations throughout tumors. Models based on mass balance, transport phenomena and reaction kinetics are powerful tools able clarify the connection between the genetic aberrations and the compositional heterogeneity of tumors. Therapeutic strategies designed using engineering principles will be able to overcome transport barriers and create more effective therapies.

Single treatments of radiation or chemotherapy often do not kill all cancer cells within a tumor. Between treatments, surviving cells proliferate and regrow as tumors and metastases, eventually leading to death. Chaotic and irregular tumor vasculature and high interstitial pressure prevent blood-borne chemotherapeutics from diffusing equally throughout all tumor regions. Additionally, non-proliferating cells, distant from vasculature, survive chemotherapeutic therapies specifically targeted to proliferating cells. Radiation therapy is also less effective in the low oxygen regions distant from vasculature because it depends on the formation of oxygen radicals. Furthermore, low oxygen environments have been shown to select for more aggressive and metastatic cells.

In my laboratory we characterize and utilize tumor heterogeneity to develop novel cancer therapies that overcome the limitations of current cancer therapies. Unique three-dimensional tumor models are designed to mimic the metabolic variations observed in tumors in vivo. The metabolic profiles of the tumor models, both in vitro and in vivo, are characterized using fluorescence microscopy, nuclear magnetic resonance spectroscopy and metabolic flux analysis.

Targeted Bacteriolytic Therapy

To specifically target tumors we are investigating motile, facultative anaerobic bacteria that specifically target and accumulate within the therapeutically inaccessible regions of tumors. Over the past 50 years numerous strains of bacteria have been shown to localize and cause lysis in transplanted mouse tumors, but their application has had minimal success in the clinic. By specifically targeting bacteria to specific sub-regions of tumors we hope to dramatically increase their affectivity.

Bacteria selected by these strategies have numerous uses. Administered alone, selected bacteria will compete with the tumor for nutrients, killing cells in inaccessible tumor regions. A combination of bacteriolytic therapy and standard anti-proliferative chemotherapy, which selectively kills proliferating cells growing close to vasculature, will attack tumors from both the inside and out. Additionally, selected bacteria could deliver therapeutic agents or amplification agents (e.g. toxins, prodrug cleaving enzymes or anti-angiogenic factors), or could express markers detectable by MRI, PET, or another imaging device.

Localized Quantification of Tumor Metabolism

In addition to diffusion, cells with different metabolic profiles cause component gradients and distinct regions of proliferation in tumors. Most people over 50 have pre-malignant lesions throughout their breasts and prostates. These lesions are kept small (<1mm) by a balance of cell proliferation and death. Cells at the centers die because of nutrient depletion and waste toxicity. Once the lesions develop vasculature, proliferation exceeds death and the tumor grows. Thus, both metabolism and diffusion play key roles in the early formation of tumors.

In my laboratory we quantify the metabolic state of different tumor regions in order to map nutrient gradients and explain mechanistically why cell growth diminishes away from vasculature. Metabolic flux analysis determines the flow of carbon through the pathways of primary and secondary metabolism using nuclear magnetic resonance spectra of extracted cellular cytoplasm. Whole cell models of metabolism are capable of i) quantifying metabolite transport across biological membranes, ii) quantifying changes in enzyme activity due to extracellular signals and iii) detect inactive pathways. In addition to explaining cancer cell proliferation, metabolic flux analysis will identify enzymatic targets for inhibitors of metabolism and proliferation in the different tumor regions.

Bacterial Migration and Segregation in Solid Tumors

In collaboration with Baystate Medical Center we are investigating how bacteria segregate in tumors. The ability of bacteria to migrate within a tumor defines their usefulness for drug delivery. We use surgical, histological and standard staining techniques to measure the rate of bacterial spread throughout subcutaneous tumors in mice following systemic injection. These experiments were designed to determine the mechanism of specific bacterial localization in tumors.

Selected Publications

  1. Forbes NS. 2010. Engineering the perfect (bacterial) cancer therapy. Accepted for publication in  Nature Reviews Cancer
  2. Venkatasubramanian R, Arenas RB, Henson MA, Forbes NS. 2010. Mechanistic modeling of dynamic MRI data predicts that tumor heterogeneity decreases therapeutic response. Br J Cancer. 103:486-97
  3. Kim BJ, Han G, Rotello VM, Forbes NS. Tuning payload delivery in tumor cylindroids using gold nanoparticles. Nat Nanotechnol. 5:465-72
  4. Hunnewell M†, Forbes NS. 2010. Active and inactive metabolic pathways in tumor spheroids: determination by GC-MS. Biotechnol Prog. 26:789-96
  5. Ganai S, Arenas RB, Forbes NS. 2009. Tumor-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice. Br J Cancer. 101:1683
  6. Walsh CL†, Babin BM†, Kasinskas RW, Foster JA†, McGarry MJ†, Forbes NS. 2009. A multipurpose microfluidic device designed to mimic microenvironment gradients and develop targeted cancer therapeutics. Lab on a Chip. 9:545-554
  7. Ghosh PS, Kim CK, Han G, Forbes NS, Rotello VM. 2008. Efficient gene delivery vectors by tuning the surface charge density of amino-acid functionalized gold nanoparticles. ACS Nano. 2:2213-8
  8. Forbes NS. 2008. A module to foster engineering creativity: an interpolative design problem and an extrapolative research project. Chemical Engineering Education 42:166-172
  9. St. Jean A, Zhang M, Forbes NS. 2008. Bacterial therapies: completing the cancer treatment toolbox. Current Opinions in Biotechnology. 19:511-517
  10. Kim BJ, Forbes NS. 2008.Single cell sorting in cylindroids demonstrates how nutrient deprivation creates apoptotic and quiescent cell populations in tumors. Biotechnology and Bioengineering. 101:797-810
  11. Venkatasubramanian R, Henson MA, Forbes NS. 2008. Incorporating cell cycle progression and drug penetration into metabolic models of multicellular tumor spheroid growth. Journal of Theoretical Biology. 253:98–117
  12. Kasinskas RW, Forbes NS. 2007. Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis. Cancer Res. 67:3201-9
  13. Kim BJ, Forbes NS. 2007. Flux analysis shows that hypoxia-inducible-factor-1-alpha minimally affects intracellular metabolism in tumor spheroids. Biotechnol Bioeng. 96:1167-82
  14. Forbes NS. 2006. Profile of a bacterial tumor killer. Nat. Biotech. 24:1484-1485
  15. Forbes NS, Meadows AL, Clark DS, Blanch HW. 2006. Estradiol stimulates the biosynthetic pathways of breast cancer cells: detection by metabolic flux analysis. Metabolic Engineering. 8:639-652
  16. Venkatasubramanian R, Henson MA, Forbes NS. 2006. Incorporating energy metabolism into a growth model of multicellular tumor spheroids. J Theor Biol. 242:440-453
  17. Kasinskas RW, Forbes NS. 2006. Salmonella typhimurium specifically chemotax and proliferate in heterogeneous tumor tissue in vitro. Biotechnology Bioengineering, 94:710-721
  18. Han G, You CC, Kim BJ, Turingan RS, Forbes NS, Martin CT, Rotello VM. 2006. Light-regulated release of DNA and its delivery to nuclei by means of photolabile gold nanoparticles. Angew Chem Int Ed Engl. 45:3165-3169
  19. Hong R, Han G, Fernandez JM, Kim BJ, Forbes NS, Rotello VM. 2006. Glutathione-mediated delivery and release using monolayer protected nanoparticle carriers. J Am Chem Soc. 128:1078-9

Back to top